

Investigation of antibacterial activity of silver nanoparticles against staphylococcus aureus strain

Silver nanoparticles

Suna Kızılyıldırım¹, Cansu Önen Güneri²¹Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Suleyman Demirel University, Isparta²Department of Medical Laboratory Techniques, University of Health Sciences Turkey, Ankara, Turkey

Abstract

Aim: Staphylococcus aureus (*S. aureus*) is an important pathogen that causes hospital and community infections. Silver nanoparticles (AgNPs) have antimicrobial activity against both gram-positive and gram-negative bacteria. Colloidal silver (Ag) based antiseptics have become more popular once again because of the increase in antibiotic resistance. Silver nanoparticles mostly show their effectiveness against bacteria by disrupting bacterial DNA replication and bacterial cytoplasm membranes. In this study, it was aimed to investigate the antibacterial effect of silver nanoparticles against *S. aureus* strain.

Material and Methods: The antibacterial effect of AgNPs was investigated against *S. aureus* ATCC 6538 reference strain. The Broth dilution method was used in the analysis of Minimum Inhibitory Concentration (MIC) values of silver nanoparticles. Brain Heart Infusion (BHI) agar plates were used in the Minimum Bactericidal Concentration (MBC) test.

Results: The investigation showed that silver nanoparticles, at a concentration of 1 mg/ml, were effective against *S. aureus*.

Discussion: As a result, the antibacterial activity of silver nanoparticles has been determined and further research is required.

Keywords

Staphylococcus Aureus, Silver Nanoparticles, Antibacterial

DOI: 10.4328/ACAM.21563 Received: 2022-12-26 Accepted: 2023-02-02 Published Online: 2023-02-22 Printed: 2023-03-25 Ann Clin Anal Med 2023;14(Suppl 1):S15-17

Corresponding Author: Cansu Önen Güneri, Department of Medical Laboratory Techniques, University of Health Sciences, 06018, Ankara, Turkey.

E-mail: cansuonlen@gmail.com P: +90 312 304 63 90

Corresponding Author ORCID ID: <https://orcid.org/0000-0002-6112-0693>

Introduction

Staphylococcus aureus (*S. aureus*) is both a human pathogen and a commensal bacterium [1]. It causes many infections such as skin and soft tissue infections, pneumonia, bacteremia, infective endocarditis, septic arthritis, and osteomyelitis [2].

The widespread use of antibiotic or antimicrobial agents has led to global concerns such as the rapid emergence of antimicrobial-resistant strains, long-term treatment of infection and increased risk of mortality [3,4]. Because of bacterial evolution and widespread antibiotic use, drug resistance of *S. aureus* has significantly increased in recent years [5]. Effective agents against antibiotic-resistant *S. aureus* infections are needed.

Silver nanoparticles (AgNPs) smaller than 100 nm in at least one dimension have drawn a lot of interest due to their antimicrobial effect [6]. Ag-based antiseptics have become more popular once again because of the increase in antibiotic resistance [7]. Colloidal silver (Ag) has been reported to be effective against gram-positive and gram-negative bacteria [8]. Their strategy for attacking staphylococci involves causing permanent harm to bacterial cells by preventing bacterial DNA replication, degrading bacterial cytoplasm membranes, or affecting intracellular adenosine-5'-triphosphate (ATP) levels [9].

In this study, we aimed to examine the antibacterial effect of Ag-NPs on the *S. aureus* ATCC 6538 strains.

Material and Methods

The study was carried out at Çukurova University, Medical Microbiology Department between 25.03.2022 and 10.08.2022. AgNPs synthesis was performed according to a previously described method [6]. The *S. aureus* ATCC 6538 reference strain was used to investigate the antibacterial efficacy of silver nanoparticles. This study was conducted in accordance with ethical rules.

Minimum Inhibitory Concentration (MIC) Determination

A standard broth microdilution in MHB was used for the 96-well microtiter plates used for the AgNPs susceptibility testing in accordance with recommendations from the Clinical and Laboratory Standards Institute (CLSI). The test strain was exposed to 0.25–4 mg/mL AgNPs to determine the MICs of AgNPs. Phosphate-buffered saline was used to prepare AgNPs solutions [10].

Minimum Bactericidal Concentration (MBC) Determination

Aliquots of 50 µl from each tube that exhibited no bacterial growth were inoculated on BHI agar plates after the MIC of the AgNPs was determined. The plates were incubated for 24 hours at 37°C [11].

Results

According to the study, the value of AgNPs is efficient against *S. aureus* strain at 1, 2, and 4 mg/mL concentration. BHI agar plate was inoculated with the suspension from the tubes containing 1, 2, and 4 mg/ml. At any of the concentrations (1, 2, or 4 mg/ml), no bacterial growth occurred. As a result, the MIC and MBC values of AgNPs were found to be effective at 1 mg/ml dilution against *S. aureus* strain.

Discussion

S. aureus is a clinically significant bacterium and a serious public health concern [12]. *S. aureus* infections, particularly those brought on by antibiotic-resistant strains, are becoming a worldwide epidemic [13].

Ag-NPs have been reported to represent a new generation of antimicrobials [14]. AgNPs are non-toxic and exhibit broad-spectrum antibacterial effects [15]. The antibacterial activity of silver particles against the *S. aureus* strain was investigated in the study. At a concentration of 1 mg/ml, silver particles in the study were found to be effective against *S. aureus*.

AgNPs have been determined to completely inhibit bacterial growth at a concentration of 4µg/ml [6]. Additionally, it has been observed that Ag⁺ ions and Ag-based compounds are effective against resistant bacteria like Methicillin-resistant *S. aureus* [16]. It has been reported that AgNPs are efficient against *S. aureus* and that other investigations have shown similar results. The silver particles' low MIC values demonstrated their effective anti-staphylococcal activity and offered a hope for the future with more clinical applications [17].

Ag nanoparticles show great potential as antimicrobial agents. It has been reported that Ag nanoparticles can lead to valuable discoveries in various fields such as medical technology and antimicrobial systems [18].

Consequently, AgNPs were found to be effective against *S. aureus* and more comprehensive studies should be done.

Acknowledgment

We would like to thank Professor Dr. Fatih Köksal for contributing to the experiments and the use of laboratory facilities. We would like to thank Professor Dr. Hikmet Çoğun for assistance in nanoparticle synthesis.

Scientific Responsibility Statement

The authors declare that they are responsible for the article's scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.

Animal and human rights statement

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. No animal or human studies were carried out by the authors for this article.

Funding: None

Conflict of interest

None of the authors received any type of financial support that could be considered potential conflict of interest regarding the manuscript or its submission.

References

1. Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev.* 2015;28(3):603-61.
2. Giulieri SG, Tong SYC, and Williamson DA. Using genomics to understand methicillin- and vancomycin-resistant *Staphylococcus aureus* infections. *Microbial Genomics.* 2020; 6(1): e000324.
3. Yah CS, Simate GS. Nanoparticles as potential new generation broad spectrum antimicrobial agents. *Daru.* 2015;23:43.
4. Gurnathan S. Biologically synthesized silver nanoparticles enhances antibiotic activity against Gram-negative bacteria. *Journal of Industrial and Engineering Chemistry.* 2015;29:217-26.
5. Guo Y, Song G, Sun M, Wang J, Wa Y. Prevalence and Therapies of Antibiotic-Resistance in *Staphylococcus aureus*. *Front Cell Infect Microbiol.* 2020;10:107.
6. Mirzajani F, Ghassempour A, Aliahmadi A, Esmaeili MA. Antibacterial effect of silver nanoparticles on *Staphylococcus aureus*. *Res Microbiol.* 2011;162(5):542-9.
7. Jones SA, Bowler PG, Walker M, Parsons D. Controlling wound bioburden with a novel silver-containing Hydrofiber dressing. *Wound Repair Regen.* 2004;12(3):288-94.
8. Platania V, Kaldeli-Kerou A, Karamanidou T, Kouki M, Tsouknidas A, Chatziniokolaidou M. Antibacterial Effect of Colloidal Suspensions Varying in Silver Nanoparticles and Ions Concentrations. *Nanomaterials (Basel).* 2021;12:31.

9. Franci G, Falanga A, Galdiero S, Palomba L, Rai M, Morelli G, et al. Silver Nanoparticles as Potential Antibacterial Agents. *Molecules*. 2015;20(5):8856–74.
10. Yuan YG, Peng QL, Gurunathan S. Effects of Silver Nanoparticles on Multiple Drug-Resistant Strains of *Staphylococcus aureus* and *Pseudomonas aeruginosa* from Mastitis-Infected Goats: An Alternative Approach for Antimicrobial Therapy. *Int J Mol Sci*. 2017;18(3): 569.
11. Parvekar P, Palaskar J, Metgud S, Maria R, Dutta S. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of silver nanoparticles against *Staphylococcus aureus*. *Biomater Investig Dent*. 2020;7(1):105-9.
12. Gagliotti C, Högberg LD, Billström H, Eckmanns T, Giske CG, Heuer OE, et al. *Staphylococcus aureus* bloodstream infections: diverging trends of methicillin-resistant and methicillin-susceptible isolates, EU/EEA, 2005 to 2018. *Euro Surveill*. 2021;26(46):2002094
13. Stefani S, Goglio A. Methicillin-resistant *Staphylococcus aureus*: related infections and antibiotic resistance. *Int J Infect Dis*. 2010;14(4):19-22.
14. Li WR, Xie XB, Shi OS, Duan SS, Ouyang YS, Chen YB. Antibacterial effect of silver nanoparticles on *Staphylococcus aureus*. *Biometals*. 2011;24(1):135-41.
15. Baker C, Pradhan A, Pakstis L, Pochan DJ, Shah SI. Synthesis and antibacterial properties of silver nanoparticles. *J Nanosci Nanotechnol*. 2005;5(2):244-9.
16. Lara HH, Garza-Treviño EN, Ixtapan-Turrent L, and Singh DK. Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. *J Nanobiotechnology*. 2011;9:30.
17. Swolana D, Wojtyczka RD. Activity of Silver Nanoparticles against *Staphylococcus* spp. *Int J Mol Sci*. 2022;23(8): 4298.
18. Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, Lee HJ, et al. Antimicrobial effects of silver nanoparticles. *Nanomedicine*. 2007;3(1):95-101.

How to cite this article:

Suna Kızılyıldırım, Cansu Önen Güneri. Investigation of antibacterial activity of silver nanoparticles against *staphylococcus aureus* strain. *Ann Clin Anal Med* 2023;14(Suppl 1):S15-17